Drug intelligence / Profile preview

ZKA64

Development stage: Preclinical
Lead developer: Vir Biotechnology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ZKA64 is a highly potent anti-Zika antibody that was isolated by Humabs BioMed as part of an international research collaboration. It is being developed as a therapeutic agent to prevent congenital Zika infections. Vir Biotechnology acquired Humabs BioMed, thereby integrating ZKA64 into its infectious disease pipeline.

Targets

ZIKV EDIII (Zika virus envelope protein domain III)

Beyond the preview

Go deeper on ZKA64.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZKA64.

Explore the full profile